Mankind Pharma to buy 70% of Belgian CAR-T developer ACTx for EUR 48 million — its entry into cell therapy
The board raised its Netherlands arm's investment limit to EUR 50 million to fund the all-cash, instalment purchase. The stock closed about 1.55% lower the next session.
₹2,311.20 Oct 16, −1.55% vs Oct 15 close
LARGE-CAP by market cap ≈ ₹95,452 Cr
EUR 48 million
for 70% of ACTx, cash, in instalments
EUR 50 million
Netherlands arm's limit, up from EUR 5 million
−12.5% high ₹2,642 on Jul 29
₹574.09 Cr
consolidated, +29.1% YoY
Mankind Pharma's board, meeting on October 15, 2026 between 6:00 p.m. and 7:00 p.m. IST, approved two linked items: an additional investment of up to EUR 45 million in Mankind Pharma (Netherlands) B.V., its wholly owned Dutch subsidiary — raising that arm's aggregate investment limit to EUR 50 million, inclusive of a previously approved EUR 5 million — and, through that subsidiary, the acquisition of a 70% majority stake in Armed Cell Therapeutics B.V. ("ACTx"), a Belgium-incorporated biotechnology company developing next-generation CAR-T (chimeric antigen receptor T-cell) therapies for cancer. The filings reached the exchange after market close, between 7:23 p.m. and 7:31 p.m. IST.
EUR 48 million, all cash, paid in instalments through a two-month-old Dutch subsidiary
Board approves 70% acquisition of Armed Cell Therapeutics via Mankind Netherlands
Mankind Netherlands will invest EUR 48 million in instalments to acquire 70% of ACTx under a definitive agreement; consideration is cash. The Regulation 30 disclosure lists the completion timeline as "as per definitive agreement" and governmental approvals "as may be required in compliance with laws of the host country". ACTx's pipeline is next-generation "armed" CAR-T assets, with lead programs targeting non-Hodgkin lymphoma and small cell lung cancer, and R&D teams in the US and EU.
Read:The company's press release calls this a "strategic entry into next-generation CAR-T therapies" — a clinical-stage oncology category in which Mankind's own filing describes its existing business as domestic formulations and consumer healthcare. The financial commitment is defined and capped by the EUR 50 million subsidiary limit; what the filing does not state is any revenue, milestone schedule or expected completion date.
BSE filing — Regulation 30 acquisition announcement, Oct 15, 2026The acquisition vehicle is new. Mankind Pharma (Netherlands) B.V. was incorporated on August 13, 2026 — the filing records its business objective as holding investments in R&D assets and undertaking business development in niche therapies, through joint ventures or strategic stakes — and, being recently incorporated, it has nil turnover. The investment into the Dutch arm is a related-party transaction exempt under Regulation 23(5) as a wholly-owned-subsidiary transaction; the onward investment into ACTx is not a related-party transaction. Paying EUR 48 million for 70% implies a valuation of roughly EUR 68.6 million for the whole of ACTx — an inference from the stake arithmetic, not a figure the filing states.
Innovation will be one of the defining growth engines for Mankind over the coming decades. This investment is the first step in building a global pipeline of breakthrough therapies.
— Arjun Juneja, Chief Operating Officer, Mankind Pharma — press release, Oct 15, 2026
ACTx brings a named, senior founding team: Dr. Paul Stoffels, Chair of the Board, former CEO of Galapagos and former Chief Scientific Officer of Johnson & Johnson; Dr. John Mellors, Chief Scientific Officer and Distinguished Professor of Medicine at the University of Pittsburgh; and Peter Verhaeghe, former Chair of argenx. The press release describes the scientific premise: armed CAR-T cells carry additional engineered payloads to sustain anti-tumour activity, targeting more than one cancer antigen, with in vivo CAR-T generation among the approaches ACTx will pursue. The company is headquartered in Belgium with research operations in Pittsburgh and early development activities in Europe, Asia and the United States.
Two months of portfolio reshaping preceded this
Mankind Pharma (Netherlands) B.V. incorporated, with the stated objective of holding R&D investments and business development in niche therapies.
Exclusive in-licensing and marketing agreement with China's Chongqing Chenan Biopharmaceutical for Insulin Degludec and the Degludec + Aspart combination for India.
Board takes note of Bharat Serums and Vaccines (BSVL) — a material wholly owned subsidiary, 96% held directly — preparing to initiate voluntary liquidation as part of its integration.
Sale of 100% of Broadway Hospitality Services to AKRK Projects LLP and its partners completed; Broadway ceases to be a subsidiary.
BSVL members approve voluntary liquidation at an EGM, subject to creditors' approval under the Insolvency and Bankruptcy Code's voluntary liquidation process.
Board approves the EUR 48 million, 70% ACTx acquisition through the Netherlands subsidiary.
Read together, the filings suggest a deliberate sequence rather than a one-off: a non-core hospitality asset sold, the BSV legal entity being wound into the parent after its integration, an in-licensed injectable diabetes product added, a European holding vehicle created in August — and now that vehicle's first acquisition, eight weeks after incorporation. That reading is an inference from the timeline; the company itself describes the ACTx investment as part of a "long term strategy to build a global innovation-led pharmaceutical business".
How the stock has traded into the announcement
The announcement landed on a soft tape. At ₹2,311.20 the stock sits 12.5% below its 52-week high of ₹2,642 (July 29) and had already fallen on five of the eight sessions before the filing, from ₹2,535 on October 1. The first session after the filing closed the stock lower still — a ₹2,311.20 close on October 16, down 1.55% from Thursday's ₹2,347.60 close. Whether that move reflects the acquisition, the broader slide it extends, or both, cannot be separated from one session's trading; the close sits well inside the 52-week band of ₹1,909.70–₹2,642.
The balance sheet behind the cheque
Q3 FY26 and Q4 FY26 carried exceptional items of ₹−106.59 Cr and ₹−23.16 Cr respectively. Source: exchange filings.
The latest reported quarter, Q1 FY27, shows consolidated revenue of ₹4,030.59 Cr (up 12.9% over Q1 FY26's ₹3,570.35 Cr) and net profit of ₹574.09 Cr (up 29.1% from ₹444.62 Cr), with the operating margin at 26.2% — the strongest quarter in the five shown, with no exceptional items. Promoters held 72.63% as of June 30, 2026, essentially unchanged from 72.66% a quarter earlier. The filings give no rupee equivalent for the EUR 48 million outlay, so this report does not convert it; what can be said is that the commitment is capped, staged in instalments, and routed through a subsidiary whose approved investment limit the board set at EUR 50 million in the same meeting.
The filings that would move this story
Oct 26 board meeting
Q2 FY27 and half-year results are scheduled for Monday, October 26 — the first chance to hear whether management elaborates on the ACTx plan alongside numbers.
Completion filing
The timeline is "as per definitive agreement"; a completion announcement would confirm the instalment schedule and any host-country approvals obtained.
Tranche disclosures
The EUR 45 million additional investment into Mankind Netherlands can go in one or more tranches — further Regulation 30 filings would mark the money actually moving.
BSVL creditors' approval
The parallel voluntary liquidation of Bharat Serums and Vaccines still needs creditors' approval under the IBC voluntary liquidation process.
What the October 15 filings establish is precise and narrow: a capped, all-cash, instalment-funded purchase of 70% of a Belgian clinical-stage CAR-T developer, executed through a Dutch subsidiary created two months earlier for exactly this kind of holding. The filings state no revenue for the target's programs, no completion date beyond the definitive agreement, and no rupee cost — the measurable facts are the EUR 48 million consideration, the EUR 50 million subsidiary limit, and lead programs in non-Hodgkin lymphoma and small cell lung cancer.
The open question is the one the filings cannot answer yet: what a domestic-formulations and consumer-healthcare company does with a next-generation cell-therapy platform run by US and EU teams. Management's stated ambition is a global pipeline of breakthrough therapies with eventual accessibility in India. The October 26 results meeting and subsequent tranche or completion filings are where that intent starts becoming verifiable.
Informational and educational content only. Not investment advice.